U.S. Markets closed

AVEO Pharmaceuticals, Inc. (AVEO)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
3.07+0.04 (+1.32%)
At close: 4:00PM EDT
People also watch
ACRXPBMDAEZSANTHCLSN
Full screen
Previous Close3.03
Open3.04
Bid3.03 x 10000
Ask3.14 x 200
Day's Range2.95 - 3.08
52 Week Range0.50 - 3.30
Volume2,633,582
Avg. Volume6,142,588
Market Cap447.14M
Beta1.40
PE Ratio (TTM)-8.08
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • AVEO Pharmaceuticals, Inc. :AVEO-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017
    Capital Cube4 days ago

    AVEO Pharmaceuticals, Inc. :AVEO-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017

    Categories: Yahoo FinanceGet free summary analysis AVEO Pharmaceuticals, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of AVEO Pharmaceuticals, Inc. – Biogen Inc., Regeneron Pharmaceuticals, Inc., ArQule, Inc., Bristol-Myers Squibb Company, Amgen Inc., Eli Lilly and Company and Merrimack Pharmaceuticals, Inc. (BIIB-US, REGN-US, ARQL-US, BMY-US, ... Read more (Read more...)

  • AVEO Pharmaceuticals (AVEO) Q2 Loss Narrower than Expected
    Zacks10 days ago

    AVEO Pharmaceuticals (AVEO) Q2 Loss Narrower than Expected

    AVEO Pharmaceuticals (AVEO) reported narrower-than-expected adjusted loss in the second quarter. Its kidney cancer candidate, tivozanib is nearing approval in EU with positive CHMP recommendation.

  • Associated Press11 days ago

    AVEO reports 2Q loss

    The Cambridge, Massachusetts-based company said it had a loss of 30 cents per share. Losses, adjusted for non-recurring costs, came to 8 cents per share. The cancer drug company posted revenue of $351,000 ...